Persistent Survival Benefit in Patients with Untreated Disease Treated with Bortezomib Added to Melphalan and Prednisone

Get Permission

A final analysis of the phase III VISTA trial (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone) found a persistent significant benefit in overall survival with VMP (bortezomib, melphalan, prednisone) vs MP (melphalan, prednisone) in patients with multiple myeloma who were ineligible for transplantation. At a median follow-up of 60.1 months (range, 0–74 months), median overall survival was 56.4 months for patients receiving VMP vs 43.1 months for patients receiving MP, a 31% reduced risk of death (HR = 0.695; P < .001). In addition, there is “no emerging safety signal for second primary malignancies following VMP,” investigators reported in the Journal of Clinical Oncology.

A total of 682 patients at 151 sites in 22 countries were randomly assigned to receive up to nine 6-week cycles of VMP or MP and were then observed every 12 weeks or less. The overall median age was 71 years.

“[Overall survival] benefit with VMP was seen across prespecified patient subgroups (age ≥ 75 years, stage III myeloma, creatinine clearance < 60 mL/min),” the researchers reported. “However, no significant difference was observed in the small subgroup with documented high-risk cytogenetics (n = 46).”

Most patients (63% of the VMP group and 73% of the MP group) received subsequent therapy. The median time to next therapy was longer in the VMP group, 30.7 months vs 20.5 months in the MP group (HR = 0.557, P < .001). “Among patients who received subsequent therapies, survival from start of subsequent therapy was similar following VMP (median, 28.1 months) or MP (median, 26.8 months; HR = 0.914),” the authors wrote.

“Incidence proportions of all malignancies and of fatal hematologic malignancies and solid tumors were similar between arms,” the researchers reported. “Nineteen (6%) of 327 patients in the VMP arm and 13 (4%) of 328 patients in the MP arm reported second primary malignancies. Three patients (1%) in each arm had hematologic malignancies: Two patients in each arm had acute myeloid leukemia (fatal in all four patients), one patient in the MP arm had B-cell non-Hodgkin lymphoma that was fatal, and one patient in the VMP arm had myelodysplastic syndrome.”

The authors concluded that the final findings of the VISTA phase III trial “demonstrate a persistent significant [overall survival] benefit with VMP vs MP. These data are highly robust because of the large patient population and lengthy follow-up and show that VMP resulted in a substantial long-term [overall survival] benefit, with a 13.3-month increase in the median.”

San Miguel JF, et al: J Clin Oncol, December 10, 2012 (early release online).




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.